Gómez-Gutiérrez C, Manzano-Robleda MC, Uribe M, Méndez-Sánchez N

Language: English
References: 12
Page: 409-411
PDF size: 63.36 Kb.

Text Extraction

Hepatic encephalopathy (HE) is a serious neuropsychiatric complication of both acute and chronic liver disease. Historically, the role of ammonia accumulation has dominated explanations of the pathogenesis of HE. However, evidence has emerged for a role of other concurrent factors such as inflammation, hyponatremia, neurosteroids, oxidative and nitrosative stress, manganese with cerebral edema.

REFERENCES

1. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010; 7: 515-25. Doi: 10.1038/nrgastro.2010.116.

2. Liou IW. Management of end-stage liver disease. Med Clin North Am 2014; 98: 119-52. Doi: 10.1016/j.mcna.2013.09. 006.

3. Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutierrez T, Villegas-Lopez FA, Mendez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J 2013; 12: 74. Doi: 10.1186/1475-2891-12-74.

4. Sharma P, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol 2012; 27: 1329-35. Doi: 10.1111/j.1440-1746. 2012.07186.x.

5. Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2013. Doi: 10.1016/j.cgh.2013.12.021.

6. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013; 108: 1458-63. Doi: 10.1038/ ajg.2013.219.

7. Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, Uribe M, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013; 58: 325-36. Doi: 10.1002/hep.26370.

8. Smith W, Diaz GA, Lichter-Konecki U, Berry SA, Harding CO, McCandless SE, LeMons C, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr 2013; 162: 1228-34, 34 e1. Doi: 10.1016/j.jpeds.2012.11.084.

9. Guha M. Urea cycle disorder drug approved. Nat Biotechnol 2013; 31: 274. Doi: 10.1038/nbt0413-274.

10. Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Jr., Alexeeva O, Zupanets IA, et al. Randomized, doubleblind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology 2014; 59: 1073-83. Doi: 10.1002/hep.26611.

11. McGuire BM, Zupanets IA, Lowe ME, Xiao X, Syplyviy VA, Monteleone J, Gargosky S, et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 2010; 51: 2077-85. Doi: 10.1002/hep.23589.

12. Toapanta-Yanchapaxi L, Lopez-Velazquez JA, Uribe M, Mendez-Sanchez N. Minimal hepatic encephalopathy. Should we treat it? Ann Hepatol 2013; 12: 487-92.